



November 18, 2022

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides receives USFDA approval for Potassium Chloride Oral Solution”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

---

## **Strides receives USFDA approval for Potassium Chloride Oral Solution**

***Approval further strengthens the Potassium Chloride franchise for the US market  
Product to be marketed by Strides Pharma Inc. in the US market***

---

**Bengaluru, November 18, 2022** – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for **Potassium Chloride Oral Solution USP, 40 mEq/15mL (20%)** from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride Oral Solution USP, 40 mEq/15 mL (20%) of Genus Lifesciences Inc.

The approval further strengthens the Potassium Chloride franchise for the company which now comprises of Extended-Release Capsules, Extended-Release Tablets, Powder for Oral Solutions and Oral Solutions. The Company also has a pipeline of other Potassium Chloride products which are expected to be approved and launched in FY24. The entire Potassium Chloride range of products for the company has a cumulative market opportunity of ~US\$330 Mn as per IQVIA. The products will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 280 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 261 ANDAs have been approved and 19 are pending approval. The company has set a target to launch ~ 20 new products every year in the US.

### **About Potassium Chloride Oral Solution**

Potassium Chloride Oral Solution is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium rich foods or diuretic dose reduction are insufficient.

### **About Strides**

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (New York). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com)

### **For further information, please contact:**

<b><u>Strides</u></b> <b>Badree Komandur</b> Executive Director - Finance & Group CFO +91 80 6784 0747	<b><u>Corporate Communication</u></b> <b>Pallavi Panchmatia: +91 80 6784 0193,</b> <a href="mailto:pallavi.panchmatia@strides.com">pallavi.panchmatia@strides.com</a>
---	---

**Investor Relations:**

**Sandeep Baid:** +91 80 6784 0791

Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,  
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560 076

**PR Consultancy**

Fortuna PR

K Srinivas Reddy: +91 90005 27213

[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

Boni Mukherjee: +91 96186 82208

[boni@fortunapr.com](mailto:boni@fortunapr.com)